Neuphoria Therapeutics Inc. (NEUP) earnings per share
Annual history
Fiscal years 2022 – 2025
USD / SHARE 6 PERIODS
| Period | End | Diluted | Filed |
|---|---|---|---|
| FY 2025 | 2025-06-30 | -$0.23 | 2025-09-29 |
| FY 2024 | 2024-06-30 | -$18.62 | 2024-09-30 |
| FY 2023 | 2023-06-30 | -$0.24 | 2023-10-18 |
| FY 2022 | 2022-06-30 | -$0.02 | 2022-10-14 |
| FY 2022 | 2021-06-30 | -$0.01 | 2022-10-14 |
| FY 2022 | 2020-06-30 | -$0.01 | 2022-10-14 |
Quarterly history
Fiscal years 2024 – 2026
USD / SHARE 11 PERIODS
| Period | End | Diluted | Filed |
|---|---|---|---|
| Q3 2026 | 2026-03-31 | -$0.09 | 2026-05-15 |
| Q2 2025 | 2025-12-31 | -$0.77 | 2026-02-17 |
| Q1 2025 | 2025-09-30 | -$4.41 | 2025-11-14 |
| Q4 2025 | 2025-06-30 | -$5.79 | 2025-09-29 |
| Q3 2025 | 2025-03-31 | $6.55 | 2025-05-20 |
| Q2 2025 | 2024-12-31 | -$1.79 | 2025-02-14 |
| Q1 2025 | 2024-09-30 | -$0.62 | 2024-11-14 |
| Q4 2024 | 2024-06-30 | -$3.42 | 2024-09-30 |
| Q3 2025 | 2024-03-31 | -$2.83 | 2025-05-20 |
| Q2 2025 | 2023-12-31 | -$5.31 | 2025-02-14 |
| Q1 2025 | 2023-09-30 | $0.00 | 2024-11-14 |
Methodology
Annual rows come from the filer's 10-K and Q1–Q3 rows from the matching 10-Q; Q4 is derived as full-year minus nine-month YTD because XBRL doesn't tag Q4 as its own period. EPS Basic and EPS Diluted are reported directly by the filer. Per-share values are split-adjusted to the current share count (1 split since 2024).
For the exact XBRL concepts and formulas, see the methodology reference for EPS, FCF per share, the Q4 derivation, and split adjustment.
NEUP CIK 0001191070 Source: EDGAR filings · all facts